 Aytu gains global license to pivotal study-ready protein kinase C β isoform PKCβ inhibitor, AR101 enzastaurin in rare disease indications Program initially targeting vascular Ehlers-Danlos Syndrome vEDS, a rare inherited connective tissue disorder resulting in high morbidity and a significantly shortened life span with no FDA-approved treatments Rumpus co-founders Christopher Brooke and Nathaniel Massari to join Aytu executive team with responsibility for AR101 program and development of pediatric onset rare disease pipeline Company to host conference call today at 4:30 PM ET ENGLEWOOD, CO ACCESSWIRE April 12, 2021 Aytu BioPharma, Inc. NASDAQ:AYTU, a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the acquisition of a global license to AR101 enzastaurin, a pivotal study-ready therapeutic candidate initially targeting the treatment of vascular Ehlers-Danlos Syndrome vEDS from Rumpus Therapeutics Rumpus, a privately-held biopharmaceutical company focused on the treatment of pediatric onset rare and orphan diseases. vEDS is a rare genetic disorder typically diagnosed in childhood and characterized by arterial aneurysm, dissection and rupture, bowel rupture and rupture of the gravid uterus. 